Nicolet Advisory Services’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$260K Sell
1,479
-317
-18% -$57.7K 0.02% 353
2025
Q3
$327K Sell
1,796
-1,048
-37% -$186K 0.03% 308
2025
Q2
$486K Buy
2,844
+73
+3% +$12.7K 0.04% 221
2025
Q1
$454K Buy
2,771
+50
+2% +$8.21K 0.05% 205
2024
Q4
$413K Buy
2,721
+267
+11% +$41.5K 0.04% 237
2024
Q3
$373K Buy
2,454
+3
+0.1% +$448 0.04% 251
2024
Q2
$344K Buy
2,451
+400
+20% +$54.8K 0.03% 254
2024
Q1
$272K Buy
2,051
+128
+7% +$16.6K 0.03% 284
2023
Q4
$273K Buy
+1,923
New +$253K 0.03% 259

Other funds holding DGX

Nicolet Advisory Services's DGX Position: Q4 2025 in Review

Nicolet Advisory Services reduced its Quest Diagnostics (DGX) stake by 18% in Q4 2025, selling an estimated $57.7K and leaving 1,479 shares worth $260K. The position accounts for 0.02% of the portfolio, ranked #353.

Nicolet Advisory Services first reported a position in DGX in Q4 2023 and has held it in 9 quarters since. The position peaked at $486K in Q2 2025. 1,048 funds tracked by Wall St. Rank hold DGX as of Q4 2025.

  • Nicolet Advisory Services held 1,479 shares of Quest Diagnostics worth $260K as of Q4 2025.
  • Nicolet Advisory Services sold 317 Quest Diagnostics shares in Q4 2025, an estimated $57.7K.
  • Quest Diagnostics made up 0.02% of Nicolet Advisory Services's portfolio in Q4 2025, its #353 holding.
  • Nicolet Advisory Services first reported a position in Quest Diagnostics in Q4 2023 and has held it in 9 quarters since.
  • Nicolet Advisory Services's Quest Diagnostics position peaked at $486K in Q2 2025.
  • 1,048 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.

Based on Nicolet Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.